More companies than usual are beating earnings estimates and sales numbers are just as bullish for the stock market MarketWatch 2/6/2021
MARKETWATCH PREMIUM
Every earnings season, a majority of U.S. companies report earnings per share that are higher than the consensus estimates among Wall Street analysts.
So the positive “surprises” may not be so … surprising.
Turning your focus to positive
sales surprises and
sales growth might be more rewarding the market often rewards sales growth more than it does earnings growth.
Below is a list of companies that have beaten sales estimates.
Here’s an earnings-season Twitter posting from Stephanie Link, chief investment strategist at Hightower Advisors, that puts EPS in context:
RF Diplexer Market by 2027 Key Opportunities and Future Demand
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
J P Morgan Chase & Co (NYSE:JPM), Skyworks Solutions, Inc (NASDAQ:SWKS) - Halftime Report Final Trades: JPMorgan, Skyworks Solutions, More
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
88 Biggest Movers From Friday Benzinga 2/1/2021
Gainers
Siebert Financial Corp. (NASDAQ: SIEB) shares climbed 121.6% to close at $8.22 on Friday on heavy volume.
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) climbed 70.8% to close at $4.15 after the company announced the acquisition of Quellis Biosciences.
GameStop Corp. (NYSE: GME) shares added 67.9% to close at $325.00 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest. The company’s stock dropped over 44% on Thursday.
Novavax, Inc. (NASDAQ: NVAX) surged 64.9% to close at $220.94 after the company said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom.